生物靶向药物在老年哮喘治疗中应用的研究进展^*

The evolving role of biologic targeted drugs in managing asthma in elderly

摘要

哮喘是一类复杂的慢性呼吸系统疾病, 与年轻人相比, 老年人的哮喘管理更具挑战性, 主要源于其病程长、共病多、药物耐受性差等因素。生物靶向药物的出现为老年哮喘的精准治疗带来了新希望, 尤其是针对难治性或重度哮喘患者。本文回顾近年来生物靶向药物治疗老年哮喘的主要进展, 以期为老年哮喘患者安全、高效使用生物靶向药物提供一定的参考价值。

Abstract

Asthma in the elderly is a multifaceted chronic respiratory condition. Asthma management in the elderly is more complex than in young individuals, mostly due to the prolonged disease duration, increased comorbidities, diminished drug tolerance, and other contributing variables. The advent of biologic targeted pharmaceuticals has introduced renewed optimism for the precision management of asthma in the elderly, particularly for individuals with resistant or severe cases. This review examines recent significant advancements in the treatment of senile asthma using biologic targeted drugs, aiming to offer a reference for the safe and effective application of these treatments in elderly asthma patients.

关键词

生物靶向药物 / 老年 / 哮喘 / 治疗

Key words

Biologic targeted drugs / Elderly / Asthma / Treatment

参考文献

[1] Ford M L, Ruwanpathirana A, Lewis B W, et al. Aging—related mechanisms contribute to corticosteroid insensitivity in elderly asthma[J]. Int J Mol Sci, 2023, 24(7): 6347.

[2] Jia M, Agudelo Garcia P A, Ovando—Ricardez J A, et al. Transcriptional changes of the aging lung[J]. Aging Cell, 2023, 22(10): e13969.

[3] Chung Y, Huang T Y, Liao Y H, et al. 12—week inspiratory muscle training improves respiratory muscle strength in adult patients with stable asthma: a randomized controlled trial[J]. Int J Environ Res Public Health, 2021, 18(6): 3267.

[4] Woo S D, Park H S, Yang E M, et al. 8—Iso—prostaglandin F2α as a biomarker of type 2 low airway inflammation and remodeling in adult asthma[J]. Ann Allergy Asthma Immunol, 2024, 133(1): 73-80.e2.

[5] Laranjeira C, Jácome C, Amaral R, et al. Validation of the adult asthma epidemiological score: a secondary analysis of the EPI—ASTHMA population—based study[J]. BMJ Open, 2024, 14(11): e086493.

[6] Levy M L, Bacharier L B, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update[J]. NPJ Prim Care Respir Med, 2023, 33(1): 7.

[7] Isoyama S, Ishikawa N, Hamai K, et al. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real—world settings: a retrospective observational study[J]. Respir Investig, 2021, 59(4): 478-486.

[8] Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real—life study[J]. J Eur Acad Dermatol Venereol, 2021, 35(4): 958-964.

[9] Mahdaviazad H, Shahrokhi S, Masoompur S M . Socioeconomic—related determinants of asthma in the elderly[J]. J Prev Med Hyg, 2020, 61(4): E578-E583.

[10] Zein J G, Denson J L, Wechsler M E . Asthma over the adult life course: gender and hormonal influences[J]. Clin Chest Med, 2019, 40(1): 149-161.

[11] Mattila T, Vasankari T, Herse F, et al. Contrasting healthcare costs of COPD and asthma in elderly[J]. Respir Med, 2023, 220: 107477.

[12] Schleich F, Graff S, Guissard F, et al. Asthma in elderly is characterized by increased sputum neutrophils, lower airway caliber variability and air trapping[J]. Respir Res, 2021, 22(1): 15.

[13] Wang J, Zhang X, Zhang L, et al. Age—related clinical characteristics, inflammatory features, phenotypes, and treatment response in asthma[J]. J Allergy Clin Immunol Pract, 2023, 11(1): 210-219.e3.

[14] Dwyer D F, Ordovas—Montanes J, Allon S J, et al. Human airway mast cells proliferate and acquire distinct inflammation—driven phenotypes during type 2 inflammation[J]. Sci Immunol, 2021, 6(56): eabb7221.

[15] Chen M, Choo E, Yoo B, et al. No difference in omalizumab efficacy in patients with asthma by number of asthma—related and allergic comorbidities[J]. Ann Allergy Asthma Immunol, 2021, 126(6): 666-673.

[16] Soong W, Yoo B, Pazwash H, et al. Omalizumab response in patients with asthma by number and type of allergen[J]. Ann Allergy Asthma Immunol, 2021, 127(2): 223-231.

[17] Zhou J, Wang W J, Ding J, et al. Effect of Jingjiang Baiguo Ointment combined with omacizumab in the treatment of elderly patients with bronchial asthma and its impact on airway remodeling and airway inflammation[J]. Pract J Cardiac Cerebral Pneumal Vascular Dis, 2024, 32(7): 101-105.

[18] Ricciardi L, Papia F, Liotta M, et al. Omalizumab in middle—aged or older patients with severe allergic asthma—COPD overlap[J]. Postepy Dermatol Alergol, 2022, 39(1): 88-93.

[19] Johansson S, Nopp A, Öman H, et al. The size of the disease relevant IgE antibody fraction in relation to 'total—IgE' predicts the efficacy of anti—IgE (Xolair) treatment[J]. Allergy, 2009, 64(10): 1472-1477.

[20] R D, Venkitakrishnan R, Augustine J, et al. Efficacy of omalizumab therapy in an asthmatic with low IgE[J]. Case Rep Pulmonol, 2020, 2020: 8898454.

[21] Lombardi C, Comberiati P, Ridolo E, et al. Anti—IL—5 pathway agents in eosinophilic—associated disorders across the lifespan[J]. Drugs, 2024, 84(6): 661-684.

[22] Soendergaard M B, Bjerrum A S, Rasmussen L M, et al. Titration of anti—IL—5 biologics in severe asthma: an open—label randomised controlled trial (the OPTIMAL study)[J]. Eur Respir J, 2024, 64(2): 2400404.

[23] Xu Y H, Wang Y W, Guo Y S, et al. A case report of dupilumab combined with mepolizumab in the treatment of asthma with chronic sinusitis and nasal polyps uncontrolled by omalizumab[J]. Chin J Allergy Clin Immunol, 2023, 17(5): 444-449.

[24] Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, et al. REal worlD effectiveness and safety of mepolizumab in a multicentric spanish cohort of asthma patients stratified by eosinophils: the REDES study[J]. Drugs, 2021, 81(15): 1763-1774.

[25] Gall R, Jain N, Soong W, et al. Dupilumab—treated patients with asthma in the real world: the RAPID Global Registry[J]. Adv Ther, 2023, 40(3): 1292-1298.

[26] Rosso C, De Corso E, Conti V, et al. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP[J]. Eur Arch Otorhinolaryngol, 2024, 281(6): 3017-3023.

[27] Bult L, Thelen J C, Rauh S P, et al. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real—world cohort study[J]. Respir Med, 2024, 231: 107720.

[28] Prokunina O, Ishmael F T . Identification of biologic—responsive phenotypes in elderly people with eosinophilic asthma[J]. J Allergy Clin Immunol Glob, 2024, 3(1): 100196.

[29] Ottaviano G, De Corso E, Saccardo T, et al. Effectiveness of dupilumab in the treatment of adult and older adult patients with severe, uncontrolled CRSwNP[J]. J Pers Med, 2023, 13(8): 1241.

[30] Ramakrishnan R K, Bajbouj K, Al Heialy S, et al. IL—17 induced autophagy regulates mitochondrial dysfunction and fibrosis in severe asthmatic bronchial fibroblasts[J]. Front Immunol, 2020, 11: 1002.

[31] Lamb D, De Sousa D, Quast K, et al. RORγt inhibitors block both IL—17 and IL—22 conferring a potential advantage over anti—IL—17 alone to treat severe asthma[J]. Respir Res, 2021, 22(1): 158.

[32] Paplinska—Goryca M, Misiukiewicz—Stepien P, Proboszcz M, et al. The expressions of TSLP, IL—33, and IL—17A in monocyte derived dendritic cells from asthma and COPD patients are related to epithelial—macrophage interactions[J]. Cells, 2020, 9(9): 1944.

[33] Brightling C E, Nair P, Cousins D J, et al. Risankizumab in severe asthma—a phase 2a, placebo—controlled trial[J]. N Engl J Med, 2021, 385(18): 1669-1679.

[34] Menzies—Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma[J]. N Engl J Med, 2021, 384(19): 1800-1809.

[35] Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate—to—severe uncontrolled asthma (CASCADE): a double—blind, randomised, placebo—controlled, phase 2 trial[J]. Lancet Respir Med, 2021, 9(11): 1299-1312.

[36] Shinkai M, Ebisawa M, Fukushima Y, et al. One—year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study[J]. J Asthma, 2023, 60(3): 616-624.

[37] Corren J, Menzies—Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials[J]. Am J Respir Crit Care Med, 2023, 208(1): 13-24.

基金资助

^*国家自然科学基金项目(82360024)